Patients’ own cells transformed into model for studying disease and developing potential treatment
Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.
Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
“The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient’s genetic deficiency provides yet another tool for advancing the field of personalized medicine,” said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.
Read more . . .
The Latest on: Personalized Gene Therapy
[google_news title=”” keyword=”Personalized Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized Gene Therapy
- Gene therapy candidate restores vision in some patientson May 8, 2024 at 10:10 am
Discover how a CRISPR gene editing therapy improved vision for patients with a rare eye disorder in a promising phase 1/2 trial led by Mass General Brigham.
- Broken String-Crick Institute Collaboration Focuses on ALS Researchon May 8, 2024 at 7:22 am
The Crick Institute plans to leverage Broken String’s DNA break-mapping platform to develop novel applications for ALS treatments.
- Improving Gene Therapy for Lung Diseaseon May 8, 2024 at 5:59 am
Drug delivery researchers at Oregon State University have created a device that could enhance gene therapy for patients with inherited lung diseases like cystic fibrosis, according to a study led by ...
- For every million-dollar gene therapy, Peter Marks gets an email from FDA chief Robert Califfon May 8, 2024 at 3:55 am
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. “Every time we ...
- Opinion: A CRISPR breakthrough? The gene therapy has been approved to treat sickle-cell diseaseon May 7, 2024 at 3:05 pm
A new gene therapy, utilizing the gene-editing tool known as CRISPR to treat sickle-cell disease, has received approval in the U.K., the U.S., and the EU. This milestone marks a potential breakthrough ...
- Krystal Biotech touts topical gene therapy uptake, plots overseas launcheson May 7, 2024 at 10:27 am
After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for the rare skin disease dystrophic epidermolysis bullo | The ...
- Gene Therapy Improves Vision in People With Inherited Blindnesson May 6, 2024 at 6:00 am
An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindne ...
- New gene signature could transform immunotherapy for gastrointestinal cancerson April 30, 2024 at 1:31 pm
Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune ...
- What Lies Ahead? Shaping the Future of Cell and Gene Therapyon April 29, 2024 at 1:24 pm
Sponsored content brought to you by The launch of Revvity, Inc. in May 2023 signaled the rebranding of an 85-year-old company with a dedicated focus on the diagnostics and life sciences sector.
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
via Bing News